Abstract: Compounds with anti-viral properties are provided that are based on the following structures: A variety of heteroaromatic groups have been found to be biologically active against the Zika (ZIKV) virus. In some embodiments, a dimeric compound is provided with each monomer linked by a repeating glycol linking group.
Type:
Grant
Filed:
July 23, 2019
Date of Patent:
August 17, 2021
Assignees:
Research Foundation of the City University of New York, Texas Tech University System
Inventors:
Adam B. Braunschweig, Kalanidhi Palanichamy, M. Fernando Bravo, Milan A. Shlain, Himanshu Garg, Anjali Joshi
Abstract: The disclosure provides a deflazacort therapy comprising, administering to a subject suffering from Duchenne muscular dystrophy (DMD) a fixed dose of deflazacort. Also provided is a deflazacort therapy comprising, increasing the deflazacort dosage when the subject loses ambulation; or, increasing the dosage of deflazacort administered during concomitant administration of a CYP3A4 inducer; or, decreasing the dosage of deflazacort administered during concomitant administration of a CYP3A inhibitor.
Type:
Grant
Filed:
May 26, 2017
Date of Patent:
August 10, 2021
Assignee:
PTC THERAPEUTICS, INC.
Inventors:
Stephen P. Wanaski, Virginia D. Schmith, Linda L. Grasfeder, Scott Joseph Brantley
Abstract: A multidose package containing an imiquimod formulation suitable for treating topical conditions includes: a) a dispensing aperture for dispensing the formulation from the package; b) a reservoir containing sufficient formulation to provide two or more doses; c) a metered dosage element for measuring a predetermined dose of the formulation, the element including an inlet from the reservoir and an outlet to the dispensing aperture; and d) an actuating element operating the dosage element so the predetermined dose is delivered to the dispensing aperture; wherein the dose is dispensed without microbial or other contamination or degradation of the formulation in reservoir. A corresponding course of treatment for various maladies includes providing a multidose package containing an imiquimod formulation suitable for the treatment. A corresponding method of treatment of diseases with multiple doses of an imiquimod formulation includes multiple doses provided by a multidose package.
Type:
Grant
Filed:
February 20, 2019
Date of Patent:
August 3, 2021
Assignee:
BAUSCH HEALTH IRELAND LIMITED
Inventors:
Mark J. Hutchings, Christiaan M. Niekerk
Abstract: The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.
Type:
Grant
Filed:
March 30, 2016
Date of Patent:
August 3, 2021
Assignees:
Institute For Cancer Research, Institut Curie, Institut de Genetique et de Biologie Moleculaire et Cellulaire
Inventors:
Alfonso Bellacosa, Rossella Tricarico, Tim Yen, Vikram Bhattacharjee, Pietro Mancuso, Lionel Larue, Irwin Davidson
Abstract: The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-? and/or PKC-?. Non-limiting examples of an inhibitor of PKC-? and/or PKC-? include ICA-1 and ACPD. The invention also provides PKC-? and/or PKC-? as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-? and/or PKC-?. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-? and/or PKC-? based on the levels and/or activity of PKC-? and/or PKC-? mRNA or protein in the melanoma cells from the subject are also provided.
Type:
Grant
Filed:
August 28, 2019
Date of Patent:
July 20, 2021
Assignees:
UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Inventors:
Mildred Enid Acevedo-Duncan, Wishrawana Sarathi Ratnayake, David A. Ostrov
Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
Type:
Grant
Filed:
September 13, 2019
Date of Patent:
July 13, 2021
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER
Inventors:
Joan Massague, Adrienne Boire, Qing Chen
Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Type:
Grant
Filed:
May 28, 2020
Date of Patent:
June 22, 2021
Assignee:
G1 Therapeutics, Inc.
Inventors:
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Abstract: The present invention relates to a use of D-chiro-inositol, pinitol, or analog compounds thereof for preventing or treating female menopausal symptoms. The active ingredient compound of the present invention has an effect of increasing the activity of female hormones by increasing the blood concentration of 17?-estradiol and lowering the blood concentration of sex hormone-binding globulin. Therefore, the active ingredient compound of the present invention can be developed as a drug or a nutraceutical for preventing, alleviating or treating female menopausal symptoms. The active ingredient of the present invention is derived from a natural product, and thus, unlike an agonist of female sex hormones or chemically synthesized sex hormones, has very few side effects when applied to the human body.
Abstract: The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of Formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents.
Type:
Grant
Filed:
June 15, 2017
Date of Patent:
June 15, 2021
Assignee:
Cortice Biosciences, Inc.
Inventors:
Michael Weiser, Jason Stein, Donald Picker
Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol.
Abstract: Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.
Abstract: The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.
Abstract: Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.
Type:
Grant
Filed:
May 7, 2019
Date of Patent:
May 25, 2021
Assignee:
Horizon Therapeutics, LLC
Inventors:
Huai-Chueh Chang, Steven S. Pfeiffer, Vasilios H. Iskos, Maki Uragami, Steven Weissman, Andrew Thompson
Abstract: Compositions containing one or more kinds of essential amino acids other than leucine and not less than 35 mol % of leucine, relative to the total content of essential amino acids, are useful for preventing or improving dementia or a depressive state, in particular, a depressive state caused by stress, have high safety, and can be continuously ingested or administered.
Abstract: The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.
Type:
Grant
Filed:
May 11, 2020
Date of Patent:
May 18, 2021
Assignee:
THERAPEUTICA BOREALIS OY
Inventors:
Kalervo Väänänen, Lauri Kangas, Matti Rihko
Abstract: The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of Formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents.
Type:
Grant
Filed:
June 15, 2017
Date of Patent:
May 11, 2021
Assignee:
Cortice Biosciences, Inc.
Inventors:
Michael Weiser, Jason Stein, Donald Picker
Abstract: The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours.
Abstract: Copper based antibacterial agents are described based on amphiphilic copper complexes formed between copper and hydroxypyrones, such as maltol. In further aspects, the present invention relates to PEG based-ointments showing that they are particularly effective for topical delivery of amphiphilic complexes of copper. In particular, PEG ointments were shown to limit bacterial growth, even when in the absence of copper agent. However, this bacteriostatic effect is shown herein to become a true biocidal effect when copper hydroxypyrones are added to the PEG.
Type:
Grant
Filed:
February 6, 2018
Date of Patent:
May 11, 2021
Assignee:
United Kingdom Research and Innovation
Inventors:
Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria, Carlos Andre Passos Bastos
Abstract: The present application relates to use of a nitric oxide releasing agent in the preparation of a medicament for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. The present application further provides a method for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor in a subject. The method comprise administering, to a subject in need, a prophylactically or therapeutically effective amount of the nitric oxide releasing agent.
Type:
Grant
Filed:
April 22, 2020
Date of Patent:
April 27, 2021
Assignee:
ONQUALITY PHARMACEUTICALS CHINA LTD.
Inventors:
Shiyi Zhang, Zhaoyu Wu, Chao Liu, Linan Yang, Leying Chen, Jie Luo